Cardio-vascular
Refine Search
Pharmaceutical
Although drug sales in Russia fell 13% in the first four months of the current year in volume terms to 1.7 billion packages, they grew by 4.8% to 390 billion roubles ($5.4 billion) in terms of value, reports The Pharma Letter’s local correspondent. 15 June 2021
Pharmaceutical
The cost of prescription items dispensed in England in 2020/21 was £9.61 billion ($13.6 billion). This was a 3.49% increase of £324 million from £9.28 billion in 2019/20 and a 7.41% increase of £663 million from £8.94 billion in 2014/15. 10 June 2021
Biotechnology
Valo Health has announced its intention to list as a publicly-traded company, with a significant investment from backers including Khosla Ventures, Koch Disruptive Technologies and Flagship Pioneering. 10 June 2021
Pharmaceutical
Pharmsynthez, one of Russia’s leading drugmakers, will invest about 4 billion roubles ($55 million) to establish large-scale production of heart disease drugs in the Tyumen region of Russia, according to recent statements by the company and some local media reports. 8 June 2021
Biotechnology
Heartseed and Danish pharma major Novo Nordisk have entered into an exclusive worldwide collaboration and licence agreement for development, manufacturing and commercialization of the Japanese start-up’s lead asset, HS-001. 1 June 2021
Biotechnology
Following its May 2021 meetings, the European Medicines Agency’s human medicines committee (CHMP) recommended eight even medicines, including one gene therapy and one generic, for approval. 21 May 2021
Pharmaceutical
Eli Lilly’s tirzepatide has achieved all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular (CV) risk in the SURPASS-4 trial. 21 May 2021
Biosimilars
Medicines for Europe, the trade group representing the generics and biosimilars industry in Europe, has welcomed an update to the 2020 industrial strategy published by the European Commission (EC). 18 May 2021
Pharmaceutical
At the annual meeting of the American College of Cardiology (ACC), poor results for Novartis’ Entresto (sacubitril/valsartan) have disappointed. 17 May 2021
Pharmaceutical
Bristol Myers Squibb has announced a new analysis of data from the Phase III EXPLORER-HCM study of mavacamten, the firm’s investigational, first-in-class cardiac myosin inhibitor. 17 May 2021
Biotechnology
In a second licensing deal in as many days, Biogen today announced the exercising of its option to acquire TMS-007, an investigational drug for acute ischemic stroke, from Japanese biotech firm TMS Co. 12 May 2021
Pharmaceutical
Reporting first-quarter 2021 financial results, Bayer said sales of pharmaceuticals came in at 4.4 billion euros ($5.3 billion), a 4% fall from the prior-year period when currency effects are taken into account. 12 May 2021
Pharmaceutical
Japanese pharma company Sumitomo Dainippon Pharma is to acquire the exclusive development and marketing rights in China, Hong Kong, Taiwan and other Asian markets for multiple development compounds from Sinovant, a subsidiary of Roivant Sciences. 10 May 2021
Pharmaceutical
Sales of Comirnaty, Pfizer’s BioNTech-partnered coronavirus vaccine, led the firm to a better-than-expected first quarter, with revenues up 45% at $14.6 billion. 4 May 2021
Biotechnology
Markets welcomed a robust first quarter results statement from AstraZeneca, with the firm reporting revenues of $7.3 billion, an increase of 15% on the same period from last year. 30 April 2021
Biotechnology
Bristol Myers Squibb matched analysts’ revenue forecasts for the first quarter, reporting $11.1 billion in global sales, and an earnings per share (EPS) figure of $0.89. 29 April 2021
Pharmaceutical
Japan’s Daiichi Sankyo has entered into an exclusive licensing agreement with Esperion Therapeutics to market bempedoic acid (trade-named Nilemdo in some markets), its proprietary oral once-daily drug for the treatment of hypercholesterolemia, in South Korea, Brazil, Taiwan, Hong Kong, Macao, Thailand, Vietnam, Myanmar and Cambodia (the Region). 27 April 2021
Pharmaceutical
Swiss pharma giant Novartis today released first-quarter 2021 financial results, which failed to meet analysts’ expectations. 27 April 2021
Biotechnology
The European Medicines Agency’s Committee for Medicinal Products for Human US (CHMP) recommended eight medicines for approval at its April 2021 meeting, five of which were novel drugs. 23 April 2021
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a Marketing Authorization for Vazkepa (icosapent ethyl), according to Ireland-incorporated Amarin Corp. 23 April 2021
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze